scholarly article | Q13442814 |
P50 | author | Martine Amiot | Q39395922 |
Philippe Moreau | Q87734443 | ||
P2093 | author name string | Catherine Pellat-Deceunynck | |
Sophie Maïga | |||
Patricia Gomez-Bougie | |||
Catherine Godon | |||
Charlotte Kervoëlen | |||
Maxime Halliez | |||
P2860 | cites work | Molecular pathogenesis of multiple myeloma: basic and clinical updates | Q27026205 |
Emerging Bcl-2 inhibitors for the treatment of cancer | Q33682689 | ||
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma | Q34255215 | ||
The molecular classification of multiple myeloma | Q34530992 | ||
Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study | Q34637209 | ||
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines | Q34750568 | ||
Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo | Q36916903 | ||
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model | Q37223850 | ||
Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies | Q37863988 | ||
The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma | Q37946246 | ||
Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. | Q39048347 | ||
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. | Q39324268 | ||
ABT-737 is highly effective against molecular subgroups of multiple myeloma | Q39491434 | ||
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma | Q40124624 | ||
Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma | Q40397270 | ||
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. | Q40420617 | ||
Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells | Q40633129 | ||
Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells | Q41129636 | ||
Apoptotic machinery diversity in multiple myeloma molecular subtypes | Q41807395 | ||
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells | Q42543880 | ||
Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. | Q43804591 | ||
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis | Q44834826 | ||
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. | Q52546411 | ||
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 1 | |
P921 | main subject | curcumin | Q312266 |
cell death | Q2383867 | ||
P304 | page(s) | 60-65 | |
P577 | publication date | 2015-01-01 | |
P1433 | published in | Cancer Biology and Therapy | Q2544651 |
P1476 | title | Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups | |
P478 | volume | 16 |
Q37671719 | Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma |
Q39016579 | Cucurmin, anticancer, & antitumor perspectives: A comprehensive review. |
Q89388701 | Curcumin-Loaded Solid Lipid Nanoparticles Enhanced Anticancer Efficiency in Breast Cancer |
Q49736620 | Long-term stabilisation of myeloma with curcumin |
Search more.